Related Party - Gilead Sciences, Inc. - Additional Information (Details) $ / shares in Units, shares in Millions, $ in Millions	1 Months Ended				3 Months Ended			6 Months Ended		12 Months Ended
	Jan. 31, 2024 USD ($) shares	Jun. 30, 2023 USD ($) program shares	May 31, 2023 USD ($) program	Jul. 31, 2020 USD ($)	Jun. 30, 2024 USD ($) $ / shares	Mar. 31, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) $ / shares	Jun. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($) program	Dec. 31, 2020	Jan. 29, 2024 USD ($)
Related Party Transaction [Line Items]
Common stock share value						$ 228.0	$ 20.0
Contract with customer, liability, revenue recognized					$ 39.0		28.0	$ 180.0	$ 53.0
Related Party
Related Party Transaction [Line Items]
Percentage of outstanding common stock held					32.90%			32.90%
Related Party | Research and Development
Related Party Transaction [Line Items]
Reimbursement from related party for shared costs					$ 14.0		34.0	$ 30.0	67.0
Purchase Agreement | Related Party
Related Party Transaction [Line Items]
Common stock shares issued | shares	15.2	1.0
Common stock share value		$ 20.0
Funds received for stock purchase agreement	$ 320.0
Purchase price of common stock allocation to performance obligation	$ 87.0
Percentage of premium purchase price of common stock								20.00%
Trailing days average closing price								5 days
Weighted average closing price of our common stock on grant date (in dollars per share) | $ / shares					$ 33.54			$ 33.54
Purchase Agreement | Related Party | Maximum
Related Party Transaction [Line Items]
Right to purchase additional outstanding voting common stock percentage					35.00%			35.00%
Gilead Collaboration Agreement
Related Party Transaction [Line Items]
Option payment upon completion of certain IND-enabling activities											$ 60.0
Option payment upon achievement of certain development milestones											150.0
Gilead Collaboration Agreement | Related Party
Related Party Transaction [Line Items]
Collaboration term for current and future clinical programs												10 years
Option continuation payment due upon sixth anniversary of agreement													$ 100.0
Upfront cash payment				$ 175.0
Option fee per program for all other programs entering clinical development to exercise option											$ 150.0
Number of research programs | program											2
Contract with customer, liability, revenue recognized					$ 36.0		$ 29.0	$ 177.0	$ 54.0
Gilead Collaboration Agreement | Related Party | Maximum
Related Party Transaction [Line Items]
Potential regulatory approval milestones payment receivable related to domvanalimab											$ 500.0
Amended Gilead Collaboration Agreement
Related Party Transaction [Line Items]
Number of exercise option to programs | program											3
Option payments received										$ 725.0
Removal of option continuation payment under agreement											$ 100.0
Option payment upon achievement of certain development milestones			$ 150.0
Number of programs, eligible to receive regulatory and commercial milestone payments | program			2
Amended Gilead Collaboration Agreement | Related Party
Related Party Transaction [Line Items]
Upfront cash payment		$ 35.0	$ 17.5
Number of research programs | program		2
Option payment upon completion of certain IND-enabling activities			45.0
Amended Gilead Collaboration Agreement | Related Party | Maximum
Related Party Transaction [Line Items]
Regulatory and commercial milestone payments received			$ 375.0